GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025

GenSight Biologics announces financing amounting to c. €0.9 million from existing investors

GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results

GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study

GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update

GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy

GenSight Biologics announces a financing for an amount of c. €1.5 million from existing investors

GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

GenSight Biologics announces a financing for an amount of c. €2.8 million from existing investors